Clinical trialPhase 3Active not recruiting
Short-course Versus Long-course Pre-operative Chemotherapy With mFOLFIRINOX or PAXG (CASSANDRA TRIAL)
A Randomized Phase III Trial of Short-course Versus Long-course Pre-operative Chemotherapy With mFOLFIRINOX or PAXG Regimen for Stage I-III Pancreatic Ductal Adenocarcinoma (PDAC)
- Outcome
- Ongoing
- Phase
- Phase 3
- Status
- Active not recruiting
- Study type
- Interventional
- Start
- 3 November 2020
- Expected end
- 31 January 2026
- Enrollment
- 261 participants
- Sites
- 22
- Primary outcomes
- Event-free survival; Event-free survival
- Sponsor
- Other
- Results posted
- No
- Last update
- 9 April 2025
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Papers 7
- Builds on itShort-term versus long-course neoadjuvant chemotherapy for resectable and borderline resectable pancreatic ductal adeno… DOI 10.1016/j.eclinm.2026.104190↗
- Builds on itPreoperative mFOLFIRINOX versus PAXG for stage I-III resectable and borderline resectable pancreatic ductal adenocarcin… DOI 10.1016/s0140-6736(25)01685-x↗
- BackgroundA randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally adv… DOI 10.1016/j.ejca.2018.07.007↗
- BackgroundNab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PAC… DOI 10.1016/s2468-1253(18)30196-1↗
- BackgroundSafety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a… DOI 10.1016/s2468-1253(18)30081-5↗
- BackgroundPhase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresect… DOI 10.1038/bjc.2016.209↗
- BackgroundAdjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancrea… DOI 10.1245/s10434-011-2205-2↗